Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Strategic Business Report

  • ID: 1244801
  • Report
  • Region: Global
  • 120 Pages
  • Global Industry Analysts, Inc
1 of 4

FEATURED COMPANIES

  • Alcobra Ltd. (Israel)
  • Curemark, LLC. (US)
  • Neurovance, Inc. (US)
  • Pfizer Inc. (US)
  • Shire plc (Ireland)
  • Tris Pharma, Inc. (US)
  • MORE
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics in US$ Million.

Company profiles are primarily based on public domain information including company URLs. The report profiles 27 companies including many key and niche players such as -

Alcobra Ltd.
Amarantus Bioscience Holdings, Inc.
Amedra Pharmaceuticals LLC
Curemark, LLC.
Eli Lilly and Company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alcobra Ltd. (Israel)
  • Curemark, LLC. (US)
  • Neurovance, Inc. (US)
  • Pfizer Inc. (US)
  • Shire plc (Ireland)
  • Tris Pharma, Inc. (US)
  • MORE
I. Introduction, Methodology & Product Definitions
  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
II. Executive Summary 1. Market Overview
  • ADHD Therapeutics: A Primer
  • ADHD Therapeutics Market Outlook
  • Factors Driving ADHD Therapeutics Market
  • Changes in Insurance Coverage
  • Addition of Formal Guidelines
  • Low Diagnosis Threshold
  • Advancements in Field of Medicine
  • Unmet Needs
  • Launch of Pipeline Drugs
  • Factors Inhibiting ADHD Therapeutics Market
  • Side Effects Related to Use of Stimulants to Treat ADHD
  • Under-diagnosis of ADHD Condition
  • Reduced Availability of Non-Stimulants in Certain Geographies
  • Competitive Landscape
  • Major ADHD Medications Available in the Market
  • ADHD Medications Approved by FDA
  • Patent Validity for Major ADHD Drugs
2. Noteworthy Trends In Adhd Therapeutics Market
  • Biological Psychiatry Gaining Ground
  • Social Media Drives Heightened Awareness
  • Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity
  • Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market
  • Strategic Alliances
3. Developmental Pipeline Of Adhd Drugs
  • An Overview
  • ADHD Drugs under Phase II/III Development in (2015)
4. ADHD
  • AN INSIGHT
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Introduction
  • Brief History of the Disorder
  • Common Co-Occurring Disorders with ADHD
  • Consequences of ADHD
  • What Leads to ADHD?
  • Study Reveals Deficits in Protein Levels in Brain’s Reward/ Motivation System
  • ADHD Symptoms
  • Different Diagnostic Criteria for ADHD Diagnosis
  • Overview of the ICD-10 medical classification system for ADHD
  • ICD-10 Criteria for Diagnosing ADHD
  • Diagnostic Guidelines
  • ICD-10 Code for Diagnosing Hyperkinetic Disorder
  • F90.0 Disturbance of activity and attention
  • DSM Criteria for Diagnosis of ADHD
  • DSM IV Criteria for ADHD Diagnosis
  • DSM IV Criteria for Inattention and Hyperactivity/Impulsivity
  • DSM 5™ Criteria
  • DSM-5™ DIAGNOSTIC CRITERIA FOR ADHD
  • Inattention
  • Hyperactivity and Impulsivity
  • Treating ADHD
  • Stimulants
  • Non-stimulants
  • Others
  • Alternative Treatments
  • Overview of ADHD Treatment Options
  • Risks Associated with Pharmacotherapy
5. Clinical Trials
  • Supernus Announces Positive Results from Phase IIB Trials for SPN-812
  • Sunovion Announces Top-line Results from Phase II/III Clinical Trial
  • Taisho Conducts Phase II Trial for TS-141
  • Shire Announces Positive Top-Line Result from Phase III Trial of SHP465-305
  • Highland Therapeutics Initiates Phase II Trial for HLD100
  • FDA Advises Hold for Alcobra Phase III Trial MDX for ADHD
6. Products Innovations/Introductions
  • Mylan Rolls Out Dextroamphetamine Sulphate Extended Release Capsules
  • Tris Pharma Introduces Liquid DYANAVEL XR for ADHD
  • Neos Introduces Adzenys XR-ODT
  • Shire Introduces Intuniv, Non-Stimulant Treatment for ADHD
  • Shire Introduces Elvanse Adult®, Stimulant Treatment for Adult ADHD
  • Teva Adds Generic Intuniv® to Existing Line of ADHD Products
  • FDA Approves Pfizer’s QuilliChew ER™ Chewable Tablets
  • Actavis Introduces Generic Version of Intuniv
7. Recent Industry Activity
  • Shire Files New Drug Application for Chewable Vyvanse
  • Medgenics Acquires neuroFix Therapeutics
8. Focus On Select Global Players
  • Alcobra Ltd. (Israel)
  • Amarantus Bioscience Holdings, Inc. (US)
  • Amedra Pharmaceuticals LLC (US)
  • Curemark, LLC. (US)
  • Eli Lilly and Company (US)
  • Intellipharmaceutics International, Inc. (US)
  • Janssen Global Services, LLC (US)
  • Mallinckrodt PLC (Ireland)
  • Mylan N.V. (The Netherlands)
  • Neos Therapeutics, Inc. (US)
  • Neurovance, Inc. (US)
  • Noven Pharmaceuticals, Inc. (US)
  • Pfizer Inc. (US)
  • Shire plc (Ireland)
  • Supernus Pharmaceuticals, Inc. (US)
  • Tris Pharma, Inc. (US)
9. Global Market Perspective
  • Table 1: World Recent Past, Current & Future Analysis for ADHD Therapeutics by Geographic Region
  • US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
  • Table 2: World Historic Review for ADHD Therapeutics by Geographic Region
  • US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
  • Table 3: World 14-Year Perspective for ADHD Therapeutics by Geographic Region
  • Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
III. Market 1. The United States
  • A.Market Analysis
  • US ADHD Therapeutics Market Set Firmly on Growth Trajectory
  • Table 4: US ADHD Market: Prices of Select ADHD Drugs (2015) (includes corresponding Graph/Chart)
  • US ADHD Prevalence Rate: Some Major Facts
  • Table 5: ADHD with Co-existing Conditions (includes corresponding Graph/Chart)
  • Major Trends Impacting the US ADHD Therapeutics Market
  • Generics Ruling the Roost in US ADHD Therapeutics Market
  • Table 6: US Market for ADFHD Drugs: Percentage Breakdown of Revenue for Stimulants and Non-stimulants (2015) (includes corresponding Graph/Chart)
  • Major ADHD drugs being sold in US market
  • Adults on the Radar of US ADHD Drugs Manufacturers
  • Table 7: US ADHD Drugs Market: Percentage Breakdown of ADHD Drug Prescriptions by Age Group & Gender (2015) (includes corresponding Graph/Chart)
  • ADHD Drug for Adults: A Trail of Misuse, Addiction and Death
  • More Prescriptions, More Issues
  • Table 8: US ADHD Drugs Market: Prescriptions Filled (2010-2015) (includes corresponding Graph/Chart)
  • More Drugs, More Complications, More Emergency Room Visits
  • Though Small in Number, Deaths Due to ADHD Drug Complications is Rising
  • ADHD in Children: A Case of One Diagnosis Too Many
  • Individual Choices of Healthcare Professionals Influencing ADHD Diagnosis
  • States Working with Federal Agencies to Tackle the Problem
  • Arkansas: A Case Study in Rectifying the Over Diagnosis Problem
  • DSM 5™ Criteria
  • DSM-5™ DIAGNOSTIC CRITERIA FOR ADHD
  • Inattention
  • Hyperactivity and Impulsivity
  • Clinical Trials
  • Products Launches
  • Strategic Corporate Developments
  • Select Major Players
  • B.Market Analytics
  • Table 9: The US Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
  • Table 10: The US Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
2. Canada
A.Market Analysis
Current & Future Analysis
Strategic Corporate Development

B.Market Analytics
Table 11: Canadian Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 12: Canadian Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. Japan
A.Market Analysis
Increased Awareness Leading to Surge in Japanese ADHD Therapeutic Market
Select ADHD Drugs in Pipeline in Japanese Market
Strategic Corporate Development

B.Market Analytics
Table 13: Japanese Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 14: Japanese Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. Europe
A.Market Analysis
Effective therapeutics and Rising Awareness Amongst Public Propelling European ADHD Market
UK ADHD Market
An Overview
ADHD Prevalence
Table 15: ADHD Prevalence in the UK: Percentage Breakdown by Gender (Fiscal Year 2009-2010 through 2014-2015)
Strategic Corporate Developments
Select Key Players

B. Market Analytics
Table 16: European Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 17: European Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. Asia-Pacific
A.Market Analysis
Asia-Pacific ADHD Therapeutics Market on the Rise

B.Market Analytics
Table 18: Asia-Pacific Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 19: Asia-Pacific Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. Latin America
A.Market Analysis
Latin American ADHD Therapeutics Market to Cross US$3 billion

B.Market Analytics
Table 20: Latin American Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 21: Latin American Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

7. Rest Of World
A.Market Analysis
Current & Future Analysis
ADHASA Enabling South African Children with ADHD to Chart New Course
Strategic Corporate Development
Alcobra Ltd. (Israel)
A Key Israeli Player

B.Market Analytics
Table 22: Rest of World Recent Past, Current & Future Analysis for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 23: Rest of World Historic Review for ADHD Therapeutics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. Competitive Landscape
Total Companies Profiled: (including Divisions/Subsidiaries)
  • The United States
  • Canada
  • Japan
  • Europe
  • The United Kingdom
  • Rest of Europe
  • Middle East
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Alcobra Ltd. (Israel)
  • Amarantus Bioscience Holdings, Inc. (US)
  • Amedra Pharmaceuticals LLC (US)
  • Curemark, LLC. (US)
  • Eli Lilly and Company (US)
  • Intellipharmaceutics International, Inc. (US)
  • Janssen Global Services, LLC (US)
  • Mallinckrodt PLC (Ireland)
  • Mylan N.V. (The Netherlands)
  • Neos Therapeutics, Inc. (US)
  • Neurovance, Inc. (US)
  • Noven Pharmaceuticals, Inc. (US)
  • Pfizer Inc. (US)
  • Shire plc (Ireland)
  • Supernus Pharmaceuticals, Inc. (US)
  • Tris Pharma, Inc. (US)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll